PURPOSE: This study assessed the safety and tolerability of therapeutic immunization against the human papillomavirus (HPV) viral oncoproteins E6 and E7 in patients with cervical cancer after chemoradiation. METHODS AND MATERIALS: MEDI0457 (INO-3112) is a DNA-based vaccine targeting E6 and E7 of HPV-16/18 that is coinjected with an IL-12 plasmid followed by electroporation with the CELLECTRA 5P device. At 2 to 4 weeks after chemoradiation, patients with newly diagnosed stage IB1-IVA (cohort 1) or persistent/recurrent (cohort 2) cervical cancers were treated with 4 immunizations of MEDI0457 every 4 weeks. The primary endpoints were incidence of adverse events and injection site reactions. Immune responses against HPV antigens were measured by ELISpot for interferon-γ (IFNγ), enzyme-linked immunosorbent assay for antibody responses and multiplexed immunofluorescence for immune cells in cervical biopsy specimens. RESULTS: Ten patients (cohort 1, n = 7; cohort 2, n = 3) with HPV16 (n = 7) or HPV18 (n = 3) cervical cancers received MEDI0457 after chemoradiation. Treatment-related adverse events were all grade 1, primarily related to the injection site. Eight of 10 patients had detectable cellular or humoral immune responses against HPV antigens after chemoradiation and vaccination: 6 of 10 patients generated anti-HPV antibody responses and 6 of 10 patients generated IFNγ-producing T cell responses. At the completion of chemoradiation and vaccination, cervical biopsy specimens had detectable CD8+ T cells and decreased PD-1+CD8+, PD-L1+CD8+, and PD-L1+CD68+ subpopulations. All patients cleared detectable HPV DNA in cervical biopsies by completion of chemoradiation and vaccination. CONCLUSIONS: Adjuvant MEDI0457 is safe and well tolerated after chemoradiation for locally advanced or recurrent cervical cancers, supporting further investigation into combining tumor-specific vaccines with radiation therapy.
PURPOSE: This study assessed the safety and tolerability of therapeutic immunization against the human papillomavirus (HPV) viral oncoproteins E6 and E7 in patients with cervical cancer after chemoradiation. METHODS AND MATERIALS: MEDI0457 (INO-3112) is a DNA-based vaccine targeting E6 and E7 of HPV-16/18 that is coinjected with an IL-12 plasmid followed by electroporation with the CELLECTRA 5P device. At 2 to 4 weeks after chemoradiation, patients with newly diagnosed stage IB1-IVA (cohort 1) or persistent/recurrent (cohort 2) cervical cancers were treated with 4 immunizations of MEDI0457 every 4 weeks. The primary endpoints were incidence of adverse events and injection site reactions. Immune responses against HPV antigens were measured by ELISpot for interferon-γ (IFNγ), enzyme-linked immunosorbent assay for antibody responses and multiplexed immunofluorescence for immune cells in cervical biopsy specimens. RESULTS: Ten patients (cohort 1, n = 7; cohort 2, n = 3) with HPV16 (n = 7) or HPV18 (n = 3) cervical cancers received MEDI0457 after chemoradiation. Treatment-related adverse events were all grade 1, primarily related to the injection site. Eight of 10 patients had detectable cellular or humoral immune responses against HPV antigens after chemoradiation and vaccination: 6 of 10 patients generated anti-HPV antibody responses and 6 of 10 patients generated IFNγ-producing T cell responses. At the completion of chemoradiation and vaccination, cervical biopsy specimens had detectable CD8+ T cells and decreased PD-1+CD8+, PD-L1+CD8+, and PD-L1+CD68+ subpopulations. All patients cleared detectable HPV DNA in cervical biopsies by completion of chemoradiation and vaccination. CONCLUSIONS: Adjuvant MEDI0457 is safe and well tolerated after chemoradiation for locally advanced or recurrent cervical cancers, supporting further investigation into combining tumor-specific vaccines with radiation therapy.
Authors: Karen S Anderson; Kristina R Dahlstrom; Julia N Cheng; Rizwan Alam; Guojun Li; Qingyi Wei; Neil D Gross; Diego Chowell; Marshall Posner; Erich M Sturgis Journal: Oral Oncol Date: 2015-05-06 Impact factor: 5.337
Authors: Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi Journal: Lancet Date: 2015-09-17 Impact factor: 79.321
Authors: Franca Piras; Romano Colombari; Luigi Minerba; Daniela Murtas; Carlo Floris; Cristina Maxia; Arianna Corbu; M Teresa Perra; Paola Sirigu Journal: Cancer Date: 2005-09-15 Impact factor: 6.860
Authors: W C Gray; P B Chretien; C M Suter; D R Revie; V T Tomazic; C L Blanchard; C Aygun; R Amornmarn; J V Ordonez Journal: Otolaryngol Head Neck Surg Date: 1985-10 Impact factor: 3.497
Authors: Michael A Chattergoon; Vera Saulino; Jason P Shames; Jamie Stein; Luis J Montaner; David B Weiner Journal: Vaccine Date: 2004-04-16 Impact factor: 3.641
Authors: Ariel E Marciscano; Ali Ghasemzadeh; Thomas R Nirschl; Debebe Theodros; Christina M Kochel; Brian J Francica; Yuki Muroyama; Robert A Anders; Andrew B Sharabi; Esteban Velarde; Wendy Mao; Kunal R Chaudhary; Matthew G Chaimowitz; John Wong; Mark J Selby; Kent B Thudium; Alan J Korman; David Ulmert; Daniel L J Thorek; Theodore L DeWeese; Charles G Drake Journal: Clin Cancer Res Date: 2018-06-13 Impact factor: 12.531
Authors: Spyros A Kalams; Scott D Parker; Marnie Elizaga; Barbara Metch; Srilatha Edupuganti; John Hural; Stephen De Rosa; Donald K Carter; Kyle Rybczyk; Ian Frank; Jonathan Fuchs; Beryl Koblin; Denny H Kim; Patrice Joseph; Michael C Keefer; Lindsey R Baden; John Eldridge; Jean Boyer; Adam Sherwat; Massimo Cardinali; Mary Allen; Michael Pensiero; Chris Butler; Amir S Khan; Jian Yan; Niranjan Y Sardesai; James G Kublin; David B Weiner Journal: J Infect Dis Date: 2013-07-08 Impact factor: 5.226